The European alliance of associations for rheumatology – recommends that serum urats must be maintained on <6 mg/dL (360 μmol/L) and <5 mg/dL (300 μm/L) in people with severe gouts. But despite the available remedies, the gout is still often reduced and its management remains sub -form. In Barcelona, ​​at the 2025 Annual Eular Congress, new data was presented on several subjects around Gout.

Gout Flair is associated with cardiovascular events. Treating gout to target serum urat levels prevents flarers, but can such treatment prevent heart events. Adordo Sipoleta and an essence of colleagues discovered whether obtaining a serum urat level of 360 μmol/L within 1 year of urat-Kaming therapy is impact on the 5-year risk of the major adverse heart events (mace). Authors used English and Swedish primary-looking data related to hospitalized and mortality records for more than 116,000 patients. Overall, 16,201 patients had a mace during the follow -up. After meta-analisis, patients who achieved low serum urat within 360 μmol/l or 1 year, had a 5-year-old mace-free overall survival and low risk of mace, which was compared to those with those.

Conclusions were similar in the discovery analysis of different mace definitions, when the follower was censored on medical dissection, when patients were excluded without serum urats available during the first year of follow-up, and when each component of the mace was considered separately. The authors stated that there was a conversation between age and urat-less strategies, as the impact size in people above 65 years of age was much higher than people aged 65 or less. Additionally, a very small number of flares were recorded in people, which achieved the serum urat target.

Development to reduce new remedies. Pozdeutinurad (AR882) is a novel and selective URAT1 inhibitor, which has demonstrated a significant continuous decrease in serum urat, as well as both clinically visible leather tophi, and the total urat crystal deposits have reduced. Robert Keenan alone presented the long-term protection and tolerance of the posedutinurd or in combination with allopurinol in gout patients with data-converted testing from a stage 2 open-plenty testing. In 18 months, most remedies-free adverse events (TEE) were mild or moderate in severity, with high number in the first 6 months. Gout Flair – as expected – the most consecutive AE was seen in the first 6 months, with a declining trend in the later period. Four serious adverse incidents were reported in three patients, but no one was considered to be related to therapy for pozdeutinurad, allopurinol, or flare prophylaxis. There were no serum creatinine height or clinically important liver functional abnormalities. Kidney stones were found in two patients – with one and without the history of nephrolithiasis – but they were considered mild to moderate, they did not require treatment, and both patients completed the study with a brief obstruction without any or only medical treatment. Authors conclude that these results support pozdeutinurad as a safe alternative to the treatment of patients with gout, including both clinically visible and sub -christol crystal statements.

Step 3 data for ruzinurad – another URAT1 inhibitor – was presented by Huihua Ding. 16-During the duration of double-blind duration, 388 patients received Rozinurd and 385 allopurinols. In the week 16, the much higher ratio in the Ruzinurd group achieved the target serum urat level of EL360 μmol/L in the last two monthly measurements, compared with the alopurinol group – 39.7% vs. 26.5%. The ratio achieving the serum urat target in week 16 was 52.6% compared to 34.5% compared to 34.5% in the Ruzinurd group – a difference that was maintained by 52. 52 -during the treatment period of the wealth, with the Tea 89.7% and 91.7%, respectively, which respectively, with ruzinurad and allopurinol groups, respectively, in allopurinol groups, respectively, allopurinol groups, aminotransferase, upper respiratory tract infections, and increased in blood creatinine. Most of the TEEs were light or moderate, but severe TEA occurred in 4.9% and 3.1% of patients respectively and in alopurinol groups. The authors conclude that Ruzinurad demonstrated better urat-loaring on alopurinol, and showed a well-tomed security profile in patients with hyperthymes associated with primary gout.